Why MoCRA Compliance Is Now the Most Important Conversation in Private Label Skincare

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) represents the most significant federal cosmetics legislation in 86 years — and its compliance requirements are now fully in effect for most manufacturers and brands. For aesthetic practices, medical spas, and dermatology offices that sell private-label or white-label skincare products, MoCRA has changed the regulatory landscape in ways that many haven't yet fully assessed.

Trilogy Laboratories, based in Fort Myers, Florida, manufactures private-label and custom skincare formulations for aesthetic practices nationwide — GMP ISO 22716 certified and MoCRA compliant. Here's what every practice that sells skincare products needs to understand about the current regulatory environment.

What MoCRA Changed — and What It Means for Practices

Prior to MoCRA, cosmetics operated in one of the most lightly regulated consumer product categories in the US — no pre-market approval, limited FDA oversight, and minimal documentation requirements. MoCRA changed this substantially.

Facility registration: Every cosmetics manufacturer and many facilities that relabel or process cosmetics must register with the FDA. This requirement applies annually. Facilities that haven't registered are operating out of compliance.

Product listing: Every cosmetic product must be listed with the FDA, including ingredients, responsible person information, and the facility where it's manufactured. This is not a one-time filing; it must be updated when formulations change.

Responsible person designation: MoCRA designates a "responsible person" for each cosmetic product — the manufacturer or the brand owner, whoever places the product on the market under their name. The responsible person bears legal responsibility for the product's safety and labeling accuracy.

Adverse event reporting: Serious adverse events associated with cosmetic products must be reported to the FDA within 15 business days. Practices that sell skincare products need to have a process for capturing and acting on patient adverse event reports.

Good manufacturing practice (GMP) requirements: MoCRA authorizes the FDA to establish GMP regulations for cosmetics. While final GMP rules are still being developed, the expectation of systematic quality controls in manufacturing is now statutory rather than voluntary.

Why Your Private Label Partner's Compliance Status Matters

A practice that puts its name on a skincare product is the "responsible person" under MoCRA — which means the practice bears the regulatory responsibility for that product's compliance, even if the actual manufacturing and formulation happens at a third-party facility.

This makes the compliance posture of the private label manufacturer critically important. A practice that chooses a manufacturer based on price alone and doesn't verify that manufacturer's FDA registration, GMP certification, and MoCRA compliance is placing its own regulatory exposure in another company's hands.

Trilogy Laboratories' GMP ISO 22716 certification and MoCRA compliance aren't marketing differentiators — they're the documentation that protects partner practices from regulatory exposure. The certificate of analysis that accompanies every Trilogy product, the formulation documentation that supports product listings, and the adverse event protocols that the Trilogy team provides are the specific compliance resources that practices need but may not be getting from less rigorous manufacturing partners.

The Opportunity Side of MoCRA Compliance

Compliance is sometimes framed purely as a risk mitigation exercise. There's an opportunity dimension as well.

MoCRA compliance demonstrates to patients and regulators that the products a practice sells have been subjected to systematic quality controls — not purchased opportunistically from an unregulated source. In an environment where consumers are increasingly scrutinizing what's in their skincare and where they buy it, a practice that can point to its skincare line's GMP-certified manufacturing and FDA-registered facility is differentiated in a meaningful way.

The practices that have already built their private-label skincare business on a MoCRA-compliant foundation are not going to face the retrofit challenge that practices currently operating with non-compliant partners will need to navigate.

Start the Conversation With Trilogy Laboratories

Trilogy Laboratories partners with aesthetic practices, medical spas, dermatology offices, and plastic surgery practices across the United States. The team — which includes chemists, a licensed pharmacist, estheticians, and brand consultants — helps practices assess their current product portfolio's compliance posture and identify the specific documentation and process steps needed to operate confidently under MoCRA.

Trilogy is located at 10060 Amberwood Road, Suite 8, in Fort Myers, Florida. Call (239) 939-5454 or visit trilogylaboratories.com to start the MoCRA conversation. The regulation is in effect — the question is whether your practice's skincare products meet the standard it requires.

The Practical Compliance Assessment for Your Current Product Portfolio

For practices that currently sell private-label or white-label skincare products, the MoCRA compliance assessment involves several specific questions:

Is your manufacturing partner FDA-registered? This is verifiable through the FDA's online facility registration database. Unregistered manufacturers are operating out of compliance, and the responsible person (your practice) shares that exposure.

Have the products in your lineup been listed with the FDA? Product listing requires ingredient disclosure, responsible person information, and facility identification. This is now a required step for every cosmetic product entering the US market.

Do you have a process for capturing patient adverse event reports? If a patient experiences a reaction to a skincare product your practice sells, you now have a legal obligation to document and assess whether it constitutes a serious adverse event requiring FDA reporting within 15 business days.

Is your manufacturing partner's GMP posture adequate? ISO 22716 certification is the international standard for cosmetics good manufacturing practice. Trilogy Laboratories' ISO 22716 certification provides the documented quality management system that MoCRA anticipates.

Practices that can't answer yes to all of these questions have compliance gaps that should be addressed before the FDA's enforcement attention turns more actively to cosmetics. The first step is an honest assessment of the current product portfolio and manufacturing relationships — and Trilogy's team is equipped to walk that assessment through with interested practices.

Trilogy Laboratories' full-service manufacturing partnership — which includes formulation development, contract manufacturing, packaging design, and regulatory compliance support — means practices don't have to navigate MoCRA compliance in isolation. The team includes chemists, a licensed pharmacist, estheticians, and brand consultants who collectively cover every aspect of what it takes to sell skincare products under a practice brand in today's regulatory environment. Call (239) 939-5454 or visit trilogylaboratories.com. The compliance conversation is overdue for many practices — the time to have it is before the FDA's enforcement focus on cosmetics becomes active, not after.